Cullinan Therapeutics, Inc.

NASDAQ:CGEM

Medical - Pharmaceuticals

Healthcare
$9.01 +4.29%

+$0.62 today

Market cap
$584.94M
Beta
0.01
P/E (TTM)
-4.0
EPS (TTM)
-$3.73
52W Low $5.68High $16.74

Volume 1.06M

Average 0.99M

CGEM Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Cullinan Therapeutics, Inc.NASDAQ: CGEM

Operating Income · Q1 FY2026 · quarter ended Mar 2026

Operating income remains negative

Q1 FY2026 operating income was -$53.7M, compared with -$55M a year earlier. Trailing-twelve-month operating income was -$240.35M.

Context

  • Operating income increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate from 7 analysts of -$204.35M (+15.4%) for the fiscal year ending Dec 2026, a step up from the -22.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$53.7M+2.8% QoQ
Last fiscal yearDec 2025
-$241.65M-22.7% YoY
LTMMar 2026
-$240.35M-15.0% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.4%+31.9%+29.5 pp
1 year-22.7%+15.4%+38.1 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(241.65M) USD
Year-over-year change
-22.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How CGEM compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -15.0% is the 8th highest of 11, against a peer median of +19.4%.
CGEM Competitors
Operating Income for CGEM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$289.66M USD+208.4%—41.3%
LEGNLegend Biotech CorporationLTM Sep 2026$34.1M USD+117.9%—2.5%
CGENCompugen Ltd.LTM Mar 2026$30.7M USD+307.5%—42.3%
MGNXMacroGenics, Inc.LTM Mar 2026-$63.66M USD+36.0%—40.5%
ALXOALX Oncology Holdings Inc.LTM Mar 2026-$91.17M USD+33.2%——
ADCTADC Therapeutics S.A.LTM Mar 2026-$118.48M USD+5.6%—149.6%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026-$156.87M USD-11.7%——
JANXJanux Therapeutics, Inc.LTM Mar 2026-$156.98M USD-38.2%—726.3%
IMTXImmatics N.V.LTM Mar 2026-€212.71M EUR-251.5%—570.3%
XNCRXencor, Inc.LTM Jun 2026-$216.08M USD-69.5%—205.8%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026-$240.35M USD-15.0%——
Peer median (excluding CGEM) —+19.4%—96.0%

Competitors are the stored peer set for CGEM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.94M0000
Cost of Revenue000306K0
Gross Profit18.94M00(306K)0
Gross Margin100.0%————
Research & Development57.75M91.95M148.16M142.9M187.4M
Selling, General & Admin29.15M40.19M42.49M53.71M54.25M
Operating Expenses86.9M(144.65M)191.09M196.61M241.65M
Depreciation & Amortization53K93K310K306K311K
EBITDA(67.43M)(132.04M)(190.34M)(167.15M)(219.57M)
EBITDA Margin-356.0%————
Operating Income(67.95M)144.65M(191.09M)(196.92M)(241.65M)
Operating Margin-358.7%————
Interest Income477K6.61M21.63M29.66M22.21M
Interest Expense00000
Other Income / Expenses469K6.67M21.87M29.46M21.77M
Income Before Tax(67.49M)151.32M(169.22M)(167.46M)(219.88M)
Pre-Tax Margin-356.3%————
Income Tax Expense042.12M(14.12M)117K0
Net Income(65.57M)111.21M(153.16M)(167.38M)(219.88M)
Net Margin-346.1%————
EPS (Basic)(1.48)2.46(3.69)(3.11)(3.72)
EPS (Diluted)(1.48)2.38(3.69)(3.11)(3.72)
Weighted Avg Shares44.29M45.16M41.51M53.77M59.05M
Weighted Avg Shares (Diluted)44.29M46.64M41.55M53.77M59.05M

Cullinan Therapeutics, Inc.

NASDAQ:CGEM

Intrinsic Alpha fair value

Locked

Current Price

$9.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.